Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011133477 - COMPOSITIONS AND METHODS FOR PREDICTION OF DRUG SENSITIVITY, RESISTANCE, AND DISEASE PROGRESSION

Publication Number WO/2011/133477
Publication Date 27.10.2011
International Application No. PCT/US2011/032935
International Filing Date 18.04.2011
IPC
G01N 33/68 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
G06F 19/10 2011.1
GPHYSICS
06COMPUTING; CALCULATING OR COUNTING
FELECTRIC DIGITAL DATA PROCESSING
19Digital computing or data processing equipment or methods, specially adapted for specific applications
10Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
C12Q 1/68 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
G01N 33/53 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/15 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
15Medicinal preparations
CPC
G01N 2440/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2440Post-translational modifications [PTMs] in chemical analysis of biological material
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/5041
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
502for testing non-proliferative effects
5041involving analysis of members of signalling pathways
G01N 33/57484
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57484involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
G01N 33/6842
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6803General methods of protein analysis not limited to specific proteins or families of proteins
6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
Applicants
  • BIOMARKER STRATEGIES, LLC. [US]/[US] (AllExceptUS)
  • CLARK, Douglas, P. [US]/[US] (UsOnly)
  • SCHAYOWITZ, Adam [US]/[US] (UsOnly)
  • CABRADILLA, Cirilo [US]/[US] (UsOnly)
Inventors
  • CLARK, Douglas, P.
  • SCHAYOWITZ, Adam
  • CABRADILLA, Cirilo
Agents
  • HAILE, Lisa, A.
Priority Data
61/325,71719.04.2010US
61/356,49518.06.2010US
61/421,17808.12.2010US
61/443,14615.02.2011US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR PREDICTION OF DRUG SENSITIVITY, RESISTANCE, AND DISEASE PROGRESSION
(FR) COMPOSITIONS ET MÉTHODES DE PRÉDICTION DE LA SENSIBILITÉ ET DE LA RÉSISTANCE À UN MÉDICAMENT, ET DE LA PROGRESSION D'UNE MALADIE
Abstract
(EN) The present invention is based on the discovery that functional stratification and/or signaling profiles can be used for diagnosing disease status, determining drug resistance or sensitivity of cancer cells, monitoring a disease or responsiveness to a therapeutic agent, and/or predicting a therapeutic outcome for a subject. Provided herein are assays for diagnosis and/or prognosis of diseases in patients. Also provided are compositions and methods that evaluate the resistance or sensitivity of diseases to targeted therapeutic agents prior to initiation of the therapeutic regimen and to monitor the therapeutic effects of the therapeutic regimen. Also provided are methods for determining the difference between a basal level or state of a molecule in a sample and the level or state of the molecule after stimulation of a portion of the live sample with a modulator ex vivo, wherein the difference is expressed as a value which is indicative of the presence, absence or risk of having a disease. The methods of the invention may also be used for predicting the effect of an agent on the disease and monitoring the course of a subject's therapy.
(FR) La présente invention concerne la découverte selon laquelle la stratification fonctionnelle et/ou les profils de signalisation peuvent être utilisés pour le diagnostic de l'état d'une maladie, la détermination de la résistance ou de la sensibilité des cellules cancéreuses à un médicament, la surveillance d'une maladie ou la sensibilité à un agent thérapeutique, et/ou la prédiction d'un résultat thérapeutique pour un patient. L'invention concerne des dosages permettant le diagnostic et/ou le pronostic de maladies chez des patients. L'invention concerne également des compositions et des méthodes qui évaluent la résistance ou la sensibilité de maladies à des agents thérapeutiques ciblés avant le début du schéma thérapeutique et qui surveillent les effets thérapeutiques du schéma thérapeutique. L'invention concerne également des méthodes permettant de déterminer la différence entre un niveau ou un état basal d'une molécule dans un échantillon et le niveau ou l'état de la molécule après stimulation d'une partie de l'échantillon vivant avec un modulateur ex vivo, la différence étant exprimée comme une valeur qui indique la présence ou l'absence d'une maladie, ou le risque de la développer. Les méthodes de l'invention peuvent également être utilisées pour prédire l'effet d'un agent sur la maladie et pour surveiller le déroulement du traitement d'un patient.
Latest bibliographic data on file with the International Bureau